Consensus Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Real-time Estimate Cboe BZX Other stock markets 10:22:30 2024-05-03 EDT			5-day change	1st Jan Change
44.57 ^USD	+2.46%		+12.26%	+189.40%

04-11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
04-10	Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition	DJ

Evolution of the average Target Price on Vera Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

90b67f6b85220e708fe87d78df467.PDJXmwtuNHNiXAb555QCsrulNdNu097iBoC3FY8ATBs.fVYi1EUIRkAyL2jBtM5m54P1XqIKh4G9Z9LcYsVKCkNXRBWrWAdwPQkLaQ~9ec2b3b8fcaf4fe9599a71218de6107c

Analyst Recommendations on Vera Therapeutics, Inc.

Wedbush Raises Vera Therapeutics' Price Target to $34 From $21 After Model Update, Maintains Neutral rating	03-21	MT
Oppenheimer Raises Vera Therapeutics Price Target to $34 From $26, Maintains Outperform Rating	01-26	MT
Raymond James Upgrades Vera Therapeutics to Strong Buy From Outperform, Raises PT to $37 From $29	01-26	MT
Wedbush Raises Vera Therapeutics' Price Target to $21 From $16, Keeps Neutral Rating	01-26	MT
Oppenheimer Initiates Coverage on Vera Therapeutics With Outperform Rating, $26 Price Target	01-25	MT
Cantor Fitzgerald Starts Vera Therapeutics With Overweight Rating	01-08	MT
Raymond James Initiates Vera Therapeutics at Outperform Rating With $29 Price Target	12-18	MT
Jefferies Upgrades Vera Therapeutics to Buy From Hold, Adjusts Price Target to $26 From $18	11-10	MT
HC Wainwright Adjusts Price Target on Vera Therapeutics to $25 From $10, Maintains Buy Rating	23-09-26	MT
Guggenheim Initiates Vera Therapeutics With Buy Rating, $27 Price Target	23-08-16	MT
Wedbush Lifts Vera Therapeutics' Price Target to $16 From $12, Keeps Neutral Rating	23-08-11	MT
HC Wainwright Adjusts Price Target on Vera Therapeutics to $10 From $11, Keeps Buy Rating	23-05-12	MT
Wedbush Raises Vera Therapeutics' Price Target to $9 From $6, Keeps Neutral Rating	23-05-12	MT
JPMorgan Lowers Price Target on Vera Therapeutics to $22 From $38, Maintains Overweight Rating	23-04-12	MT
HC Wainwright Adjusts Vera Therapeutics' Price Target to $11 From $15, Keeps Buy Rating	23-03-29	MT
Wedbush Lowers Vera Therapeutics' PT to $6 From $8, Updates Estimates to Incorporate February Secondary Offering Proceeds; Keeps Neutral Rating	23-03-29	MT
Jefferies Downgrades Vera Therapeutics to Hold From Buy, Slashes Price Target to $6 From $32	23-01-04	MT
HC Wainwright Adjusts Price Target on Vera Therapeutics to $15 From $36, Maintains Buy Rating	23-01-04	MT
Wedbush Downgrades Vera Therapeutics to Neutral From Outperform, Says Shares Likely Range-Bound in Near Term; Lowers PT to $8 From $33	23-01-04	MT
JPMorgan Adjusts Price Target on Vera Therapeutics to $38 From $35, Maintains Overweight Rating	22-11-18	MT
HC Wainwright Lifts Price Target on Vera Therapeutics to $36 From $35, Reiterates Buy Rating	22-08-22	MT
Wedbush Lifts Price Target on Vera Therapeutics to $33 From $32, Keeps Outperform Rating	22-08-10	MT
JPMorgan Starts Vera Therapeutics at Overweight With $35 Price Target	22-07-12	MT
HC Wainwright Starts Vera Therapeutics at Buy With $35 Price Target	22-05-02	MT
Wedbush Starts Vera Therapeutics at Outperform With $32 Price Target	22-04-19	MT